Ionis Pharmaceuticals IONS Ionis Operations — Net Income Loss

Similar metrics at other companies

AIZOperating Segments — Net Income Loss

$163.4M-46.7%

IQVOperating Segments — Operating Income

$229.73M+11.8%

ILMNOperating Segments — Operating Income

$226M+56.9%

IFFOperating Segments — Operating Income

$223.36M+9.0%

NDSNOperating Segments — Operating Income

$75.92M+46.1%

FEOperating Segments — Net Income Loss

$464M+3.8%

Questions, answered.

What is Ionis Pharmaceuticals's ionis operations — net income loss?

Ionis Pharmaceuticals (IONS) reported ionis operations — net income loss of -$92.53M in Q1 2026.

How has Ionis Pharmaceuticals's ionis operations — net income loss changed year-over-year?

Ionis Pharmaceuticals's ionis operations — net income loss increased by 37.0% year-over-year, from -$146.94M to -$92.53M.

What is the long-term trend for Ionis Pharmaceuticals's ionis operations — net income loss?

Over 3 years (2022 to 2025), Ionis Pharmaceuticals's ionis operations — net income loss has grown at a 12.2% compound annual growth rate (CAGR), from -$269.72M to -$381.39M.

What does ionis operations — net income loss mean?

The final profit or loss generated by the business segment.

How do you interpret ionis operations — net income loss?

A trend toward positive net income indicates the segment is moving toward self-sustainability and profitability.

How does ionis operations — net income loss compare across companies?

Comparable to segment operating profit or net income at other companies.